GO:0098574 cytoplasmic side of lysosomal membrane: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098574 describes the cytoplasmic-facing leaflet of the lysosomal membrane, including proteins embedded in, attached to, or peripherally associated with this surface.
• This compartment is the platform for lysosomal membrane permeabilization (LMP), a cell death mechanism triggered by reactive oxygen species and other stressors.
• MCOLN3 (TRPML3) is a lysosomal cation channel whose activation on the cytoplasmic side disrupts lysosomal function and blocks autophagic flux.
• SLC15A4, an endolysosomal transporter, requires conformational control at the cytoplasmic face for TASL-dependent anti-inflammatory signaling.
• Lysosomal phospholipase A2 (PLA2G15) acts on the cytoplasmic side to esterify oxysterols, linking lipid metabolism to lysosomal membrane homeostasis.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect how cytoplasmic-side proteins control lysosomal membrane biology.
Description
The cytoplasmic side of the lysosomal membrane (GO:0098574) is the leaflet of the lysosomal membrane that faces the cytosol, including any protein embedded in, attached to, or peripherally associated with it. This surface is not a passive barrier; it is a signaling and trafficking hub that integrates nutrient sensing, membrane repair, and cell death decisions. Because the lysosome is the terminal degradative organelle, its cytoplasmic face must communicate with the autophagic machinery, ESCRT-mediated membrane sealing, and cytosolic stress pathways. Researchers study GO:0098574 to understand how lysosomal membrane permeabilization (LMP) releases cathepsins and triggers cell death, and how cells protect this membrane under oxidative stress. The term is also central to pharmacology: cationic polymers such as polyethylenimine exploit the cytoplasmic leaflet for gene delivery, and nanodrugs can deliberately detonate lysosomes for therapy. Thus, GO:0098574 provides a precise ontology anchor for experiments that manipulate the cytosolic face of the lysosome.
cytoplasmic side of lysosomal membrane At A Glance
| GO ID | GO:0098574 |
|---|---|
| GO term | cytoplasmic side of lysosomal membrane |
| Ontology | cellular_component |
| Synonym | external leaflet of lysosomal membrane; external side of lysosomal membrane |
| Major function | Platform for lysosomal membrane permeabilization, autophagic signaling, and cytosolic protein recruitment |
| Associated proteins | MCOLN3, SLC15A4, PLA2G15, ESCRT components, DHX8 |
| Relevance to disease | Cancer cell death, inflammation, senescence, and lysosomal storage-related pathology |
| Experimental models | CRISPR KO, point mutation, knock-in, overexpression, and nanodrug-based LMP assays |
What Is GO:0098574?
GO:0098574 is a cellular component term defined by QuickGO as the leaflet of the lysosomal membrane that faces the cytoplasm, including any protein embedded in, attached to, or peripherally associated with it. In practice, this means the outer, cytosolic-facing surface of the lysosomal limiting membrane, together with its associated protein machinery. It is synonymous with the external leaflet or external side of the lysosomal membrane. Unlike the luminal side, which contacts hydrolases and substrates, the cytoplasmic side interacts with cytosolic proteins, signaling complexes, and the autophagic apparatus.
Why Is cytoplasmic side of lysosomal membrane Important in Cell Biology?
The cytoplasmic side of the lysosomal membrane is important because it is the decision surface where cells determine whether a lysosome remains intact or becomes a death-inducing organelle. Reactive oxygen species can permeabilize this membrane, releasing cathepsins and inhibiting autophagy, which drives cellular senescence. At the same time, the cytoplasmic face recruits ESCRT machinery for membrane sealing and repair, a process essential for lysosomal integrity. Pharmacological agents such as baicalin exploit MCOLN3 on this surface to induce lysosomal dysfunction and block autophagy in non-small cell lung cancer cells. Inflammatory signaling through SLC15A4 also depends on the conformational state of this transporter at the endolysosomal cytoplasmic face. Therefore, GO:0098574 is a high-value target for understanding cell death, inflammation, and therapeutic lysosomal modulation.
• Defines the cytosolic interface where lysosomal membrane permeabilization (LMP) initiates cell death.
• Hosts MCOLN3, whose activation causes lysosomal dysfunction and autophagy blockage in cancer cells.
• Contains SLC15A4, a transporter whose cytoplasmic-side conformation controls anti-inflammatory TASL signaling.
• Supports PLA2G15-mediated oxysterol esterification, linking lipid metabolism to lysosomal membrane biology.
• Recruits ESCRT proteins for membrane sealing and repair after damage.
• Is exploited by cationic polymers such as polyethylenimine for gene delivery.
• Can be deliberately targeted by nanodrugs to detonate lysosomes for therapy.
• Participates in RNautophagy regulation via DHX8 at the lysosomal surface.
• Provides a mechanistic explanation for senescence induced by bleomycin and oxidative stress.
• Offers a tractable target for CRISPR-based functional genomics of lysosomal membrane proteins.
What Happens During cytoplasmic side of lysosomal membrane?
Lysosomal membrane permeabilization (LMP)
In simple terms: When the lysosome's outer surface is damaged, its contents leak into the cell and can trigger cell death.
Reactive oxygen species (ROS) can attack the cytoplasmic side of the lysosomal membrane, causing lysosomal membrane permeabilization (LMP). This permeabilization releases cathepsins into the cytosol and inhibits autophagy, leading to cellular senescence in models such as bleomycin-treated cells. LMP is therefore a regulated event that converts lysosomal stress into a cell-fate decision.
MCOLN3-mediated lysosomal dysfunction
In simple terms: A channel on the lysosome's outer surface can be opened by drugs, causing the lysosome to malfunction and blocking recycling.
MCOLN3 (TRPML3) is a lysosomal cation channel exposed on the cytoplasmic side. Baicalin induces cell death in non-small cell lung cancer cells via MCOLN3-mediated lysosomal dysfunction and autophagy blockage. This demonstrates that the cytoplasmic face is a druggable node for lysosomal modulation.
SLC15A4 conformational signaling
In simple terms: A transporter on the lysosome surface must change shape to send anti-inflammatory signals.
SLC15A4 is an endolysosomal transporter whose conformation at the cytoplasmic side is locked by a small-molecule inhibitor, affecting TASL proteostatic anti-inflammatory activity. This shows that the cytoplasmic leaflet is not only a structural boundary but also a signaling platform.
ESCRT-mediated membrane sealing
In simple terms: A repair crew of proteins seals holes in the lysosome membrane from the outside.
ESCRT proteins are recruited to the cytoplasmic side of damaged membranes to seal them. This membrane sealing is essential for maintaining lysosomal integrity and preventing uncontrolled LMP. The process is a key homeostatic function of GO:0098574.
RNautophagy regulation by DHX8
In simple terms: An RNA helicase helps deliver RNA into the lysosome for degradation from the outside.
DHX8 regulates the degradation of RNA by RNautophagy, a process that requires recognition at the lysosomal surface. This links the cytoplasmic side of the lysosomal membrane to nucleic acid quality control.
Key Genes Involved in GO:0098574 cytoplasmic side of lysosomal membrane
The following genes and proteins are experimentally linked to the cytoplasmic side of the lysosomal membrane (GO:0098574) and its functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MCOLN3 | Lysosomal cation channel on the cytoplasmic side | Target for baicalin-induced lysosomal dysfunction in NSCLC |
| SLC15A4 | Endolysosomal transporter with cytoplasmic-side conformation | Anti-inflammatory TASL signaling and inhibitor development |
| PLA2G15 | Lysosomal phospholipase A2 acting on oxysterols | Oxysterol esterification and lipid metabolism |
| TASL | Adapter protein in SLC15A4 signaling | Proteostatic anti-inflammatory activity |
| ESCRT components | Membrane sealing machinery | Lysosomal membrane repair |
| DHX8 | RNA helicase in RNautophagy | RNA degradation at the lysosomal surface |
| CTSB | Cathepsin B released upon LMP | Cell death and senescence readout |
| CTSD | Cathepsin D released upon LMP | Lysosomal permeabilization marker |
| LAMP1 | Lysosomal membrane marker | Membrane integrity and localization studies |
| LAMP2 | Lysosomal membrane marker | Chaperone-mediated autophagy and integrity |
| mTOR | Nutrient sensor at the lysosomal surface | Regulation of lysosomal signaling |
| TFEB | Transcription factor downstream of lysosomal stress | Lysosomal biogenesis and autophagy |
| ATG5 | Autophagy machinery component | Autophagic flux and LMP crosstalk |
| ATG7 | Autophagy machinery component | Autophagy inhibition in senescence |
| BECN1 | Autophagy initiator | Lysosomal membrane interactions |
| PEI | Cationic polymer for gene delivery | Exploits cytoplasmic leaflet for transfection |
| Nanodrug carriers | Lysosome-targeting nanoparticles | Detonation of lysosomes for therapy |
| ROS generators | Oxidative stress inducers | LMP and senescence models |
How Is cytoplasmic side of lysosomal membrane Regulated?
The cytoplasmic side of the lysosomal membrane is regulated by oxidative stress, which induces ROS-mediated LMP and autophagy inhibition. ESCRT-mediated membrane sealing counteracts damage and maintains integrity. SLC15A4 activity is controlled by conformational locking, which modulates anti-inflammatory signaling. MCOLN3 channel activity can be regulated by pharmacological agents such as baicalin. Nutrient-sensing pathways involving mTOR and TFEB also influence lysosomal membrane dynamics and biogenesis.
cytoplasmic side of lysosomal membrane and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MCOLN3 | Non-small cell lung cancer | Baicalin-treated NSCLC cells with MCOLN3 KO |
| SLC15A4 | Inflammatory signaling | Point-mutation knock-in of SLC15A4 in immune cells |
| PLA2G15 | Lipid metabolism disorders | PLA2G15 KO cells with oxysterol treatment |
| CTSB/CTSD | Senescence and cell death | ROS-induced LMP in senescence models |
| ESCRT components | Membrane repair defects | ESCRT knockdown with lysosomal damage |
Cancer and lysosomal cell death
MCOLN3-mediated lysosomal dysfunction induced by baicalin leads to cell death in non-small cell lung cancer cells, highlighting the cytoplasmic side as a therapeutic target. Nanodrugs that detonate lysosomes represent an emerging anticancer strategy.
Inflammation and immune signaling
SLC15A4 conformational control at the endolysosomal cytoplasmic face regulates TASL proteostatic anti-inflammatory activity, linking GO:0098574 to inflammatory disease.
Cellular senescence and aging
ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence, implicating the cytoplasmic leaflet in aging-related phenotypes.
Lysosomal storage and lipid metabolism
PLA2G15 esterifies side-chain oxysterols, connecting the cytoplasmic side of the lysosomal membrane to lipid homeostasis and potential storage disorders.
From cytoplasmic side of lysosomal membrane-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MCOLN3 mediate lysosomal dysfunction? | MCOLN3 knockout in NSCLC cells |
| How does SLC15A4 conformation affect inflammation? | SLC15A4 point-mutation knock-in |
| What is the role of PLA2G15 in oxysterol esterification? | PLA2G15 knockout with lipidomics |
| Can ESCRT sealing prevent LMP? | ESCRT component knockout or tagged knock-in |
| Does DHX8 regulate RNautophagy? | DHX8 knockout with RNA degradation assays |
| Can nanodrugs detonate lysosomes? | Overexpression of lysosomal targets plus nanodrug treatment |
How to Study the cytoplasmic side of lysosomal membrane Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acridine orange staining | Lysosomal membrane integrity | LMP detection |
| LAMP1-GFP imaging | Lysosomal membrane localization | Cytoplasmic leaflet visualization |
| Proximity labeling | Protein interactions at the cytoplasmic side | ESCRT recruitment |
| CRISPR knockout screen | Gene requirement for lysosomal function | Hit discovery |
| LC3-II immunoblot | Autophagic flux | Autophagy blockage |
| Cathepsin release assay | LMP-mediated cell death | Senescence studies |
| Lipidomics | Oxysterol esterification | PLA2G15 function |
| RNA degradation assay | RNautophagy activity | DHX8 regulation |
Imaging lysosomal membrane integrity
Fluorescent dextran or acridine orange uptake assays measure lysosomal membrane permeabilization in live cells. LAMP1-GFP knock-in enables direct visualization of the cytoplasmic leaflet.
Proteomics of the cytoplasmic side
Proximity labeling or surface biotinylation can identify proteins associated with the cytoplasmic side of the lysosomal membrane. This approach reveals dynamic recruitment of ESCRT and signaling proteins.
Functional CRISPR screens
Genome-wide CRISPR knockout screens can identify genes whose loss alters LMP sensitivity or lysosomal function. Validated hits can be studied with point mutations or knock-ins.
Autophagic flux and cell death assays
LC3-II immunoblotting and cathepsin release assays link cytoplasmic-side events to autophagy blockage and cell death. These readouts are standard for evaluating lysosomal dysfunction.
How CRISPR Can Be Used to Study GO:0098574 cytoplasmic side of lysosomal membrane
Knockout
CRISPR knockout of MCOLN3, SLC15A4, or PLA2G15 can test their requirement for lysosomal membrane functions. Knockout of ESCRT components reveals defects in membrane sealing.
Point Mutation
Point mutations in SLC15A4 can lock its conformation and dissect cytoplasmic-side signaling. Disease-associated variants in lysosomal genes can be modeled to study LMP sensitivity.
Knock-in
Knock-in of tagged LAMP1 or ESCRT proteins enables live imaging of the cytoplasmic leaflet. Knock-in of reporter cassettes can quantify autophagic flux.
Overexpression
Overexpression of MCOLN3 or SLC15A4 can amplify lysosomal dysfunction or inflammatory signaling. Overexpression models are useful for nanodrug-based lysosome detonation studies.
How EDITGENE Supports cytoplasmic side of lysosomal membrane Research
Researchers studying cytoplasmic side of lysosomal membrane-related genes often need to determine whether a candidate gene is causally involved in lysosomal membrane permeabilization, autophagy, or inflammatory signaling. EDITGENE provides validated CRISPR models to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for cytoplasmic side of lysosomal membrane research.
Frequently Asked Questions About cytoplasmic side of lysosomal membrane
What is GO:0098574?
GO:0098574 is the cytoplasmic side of the lysosomal membrane, the leaflet facing the cytosol including associated proteins.
What genes are involved in cytoplasmic side of lysosomal membrane?
Key genes include MCOLN3, SLC15A4, PLA2G15, ESCRT components, and DHX8.
How is lysosomal membrane permeabilization regulated?
ROS-mediated damage and ESCRT sealing regulate LMP at the cytoplasmic side.
What is the role of MCOLN3 in lysosomes?
MCOLN3 is a lysosomal cation channel whose activation causes lysosomal dysfunction and autophagy blockage.
How does SLC15A4 signal from the lysosome?
SLC15A4 requires a specific conformation at the cytoplasmic side for TASL anti-inflammatory activity.
What diseases are linked to lysosomal membrane proteins?
Cancer, inflammation, senescence, and lipid metabolism disorders are linked to GO:0098574.
How can I study the cytoplasmic side of the lysosomal membrane?
Use LAMP1-GFP imaging, LMP assays, proteomics, and CRISPR screens.
What CRISPR models are available for lysosomal research?
Knockout, point mutation, knock-in, and overexpression models can be generated for lysosomal genes.
Can nanodrugs target the lysosomal membrane?
Yes, nanodrugs can detonate lysosomes for therapeutic purposes.
What is the role of ESCRT at the lysosome?
ESCRT proteins seal damaged lysosomal membranes from the cytoplasmic side.
Conclusion
GO:0098574, the cytoplasmic side of the lysosomal membrane, is a critical cellular component that integrates lysosomal membrane integrity, autophagy, and cell death signaling. Its associated proteins, including MCOLN3, SLC15A4, PLA2G15, and ESCRT components, are implicated in cancer, inflammation, and senescence. CRISPR-based models are indispensable for dissecting these mechanisms and developing targeted therapies.
References
- 1. Qi Z et al.. 2024. ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence.. Autophagy 20(9):2000-2016 PMID: 38762757
- 2. Boeszoermenyi A et al.. 2023. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity.. Nat Commun 14(1):6626 PMID: 37863876
- 3. Dong X et al.. 2024. Baicalin induces cell death of non-small cell lung cancer cells via MCOLN3-mediated lysosomal dysfunction and autophagy blockage.. Phytomedicine 133:155872 PMID: 39096542
- 4. Abe A et al.. 2020. Esterification of side-chain oxysterols by lysosomal phospholipase A2.. Biochim Biophys Acta Mol Cell Biol Lipids 1865(10):158787 PMID: 32777483
- 5. Xiang Y et al.. 2022. Nanodrugs Detonate Lysosome Bombs.. Front Pharmacol 13:909504 PMID: 35656308
- 6. Boussif O et al.. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.. Proc Natl Acad Sci U S A 92(16):7297-301 PMID: 7638184
- 7. Radulovic M et al.. 2018. ESCRTs in membrane sealing.. Biochem Soc Trans 46(4):773-778 PMID: 29903934
- 8. Sakai R et al.. 2025. DHX8 regulates degradation of RNA by RNautophagy.. Nucleic Acids Res 53(15) PMID: 40842239
